Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
Peter Schmid, FRCP, MD, PhD
Advertisement
Articles by Peter Schmid, FRCP, MD, PhD
Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.
Advertisement
Latest Updated Articles
Dr Schmid on Key Efficacy Findings With Dato-DXd in Metastatic TNBCPublished: October 25th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5